Acurx Pharmaceuticals, Inc. (ACXP) Monday announced that its lead antibiotic candidate, ibezapolstat, is advancing to international Phase 3 clinical trials for treating C. difficile Infection.
A recent study published in the Journal of Antimicrobial Agents and Chemotherapeutics highlights ibezapolstat's ability to preserve beneficial gut bacteria, unlike vancomycin, which is linked to higher C. difficile recurrence.
The study found that genomic differences in PolC-type DNA Polymerase III allow beneficial microbes to resist ibezapolstat, supporting gut health.
Acurx plans to leverage these findings to advance its systemic Gram-positive antibiotic program targeting MRSA and its anti-anthrax bioterrorism initiative.
ACXP is currently trading at $0.73 down 8.10 percent or $0.062 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.